• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13D filed by Atea Pharmaceuticals Inc.

    12/16/24 9:50:36 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AVIR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    Atea Pharmaceuticals, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share

    (Title of Class of Securities)


    04683R106

    (CUSIP Number)


    Braden M Leonard
    65 E Cedar - Suite 2,
    Zionsville, IN, 46077
    317-344-2447

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    12/13/2024

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    04683R106


    1 Name of reporting person

    BML Investment Partners, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    WC
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    6,808,312.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    6,808,312.00
    11Aggregate amount beneficially owned by each reporting person

    6,808,312.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.1 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b) (1) of the Securities Exchange Act of 1934.


    SCHEDULE 13D

    CUSIP No.
    04683R106


    1 Name of reporting person

    Leonard Braden Michael
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    PF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    408,000.00
    8Shared Voting Power

    6,808,312.00
    9Sole Dispositive Power

    408,000.00
    10Shared Dispositive Power

    6,808,312.00
    11Aggregate amount beneficially owned by each reporting person

    7,216,312.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    8.5 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    BML Investment Partners, L.P. is a Delaware limited partnership whose sole general partner is BML Capital Management, LLC. The managing member of BML Capital Management, LLC is Braden M. Leonard. As a result, Braden M. Leonard is deemed to be the indirect owner of the shares held directly by BML Investment Partners, L.P. Despite such shared beneficial ownership, the reporting persons disclaim that they constitute a statutory group within the meaning of Rule 13d-5(b) (1) of the Securities Exchange Act of 1934.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.001 per share
    (b)Name of Issuer:

    Atea Pharmaceuticals, Inc.
    (c)Address of Issuer's Principal Executive Offices:

    225 Franklin Street, Suite 2100, Boston, MASSACHUSETTS , 02110.
    Item 2.Identity and Background
    (a)
    BML Investment Partners, L.P. - The business address of BML Investment Partners, L.P. is 65 E Cedar Suite 2, Zionsville, IN 46077. The principal business of BML Investment Partners, L.P. is to purchase, sell, trade and invest in securities. BML Capital Management, LLC - The business address of BML Capital Management, LLC is 65 E Cedar Suite 2, Zionsville, IN 46077. The principal business of BML Capital Management, LLC is to serve as the general partner to BML Investment Partners, L.P. Braden M. Leonard Mr. Leonard's business address is 65 E Cedar Suite 2, Zionsville, IN 46077. Mr. Leonard's principal business is to serve as managing member of BML Capital Management, LLC.
    (b)
    See above.
    (c)
    See above.
    (d)
    During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (e)
    During the past five years, none of BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or a party to a civil proceeding of a judicial or administrative body of competent jurisdiction where as a result of such proceeding BML Investment Partners, L.P., BML Capital Management, LLC or Braden M. Leonard was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
    (f)
    Braden M. Leonard is a citizen of the United States of America.
    Item 3.Source and Amount of Funds or Other Consideration
     
    BML Investment Partners, L.P. holds 6,808,312 shares of Common Stock which were acquired using working capital. Braden M. Leonard individually owns 408,000 shares of Common Stock which he acquired using personal funds.
    Item 4.Purpose of Transaction
     
    The Reporting Persons purchased the Common Stock reported hereunder for investment purposes, and such purchases were made in the Reporting Persons' ordinary course of business. As with their other investments, the Reporting Persons continuously evaluate the Issuer, including but not limited to its businesses, results of operations, and prospects. On December 13th, 2024, the Reporting Persons sent a letter to the Board of Directors of the Issuer, indicating the Reporting Person's belief that the Issuer needs to find a strategic partner or explore other strategic alternatives. All of the shares of Common Stock reported herein as being beneficially owned by the Reporting Persons were acquired for investment purposes. Except as set forth herein, none of the Reporting Persons has any plans or proposals that related to or would result in any of the transactions described in Item 4 of Schedule 13D. The Reporting Persons reserve the right to acquire, or cause to be acquired, additional securities of the Issuer, to dispose of, or cause to be disposed, such securities at any time or to formulate other purposes, plans or proposals regarding the Issuer or any of its securities, to the extent deemed advisable in light of general investment and trading policies of the Reporting Persons, market conditions or other factors.
    Item 5.Interest in Securities of the Issuer
    (a)
    BML Investment Partners, L.P. beneficially owned 6,808,312 shares of the Issuer's Common Stock. Braden M. Leonard beneficially owned 7,216,312 shares of the Issuer's Common Stock
    (b)
    BML Investment Partners, L.P. beneficially owned 6,808,312 shares of the Issuer's Common Stock. Braden M. Leonard beneficially owned 7,216,312 shares of the Issuer's Common Stock
    (c)
    N/A
    (d)
    BML Investment Partners, L.P. beneficially owned 6,808,312 shares of the Issuer's Common Stock. Braden M. Leonard beneficially owned 7,216,312 shares of the Issuer's Common Stock
    (e)
    N/A
    Item 6.Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
     
    N/A
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1 - BML Letter to Board

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    BML Investment Partners, L.P.
     
    Signature:By: BML Capital Management, LLC, an Indiana limited
    Name/Title:BML Investment Partners, L.P.
    Date:12/16/2024
     
    Signature:Braden M Leonard
    Name/Title:BML Investment Partners, L.P.
    Date:12/16/2024
     
    Leonard Braden Michael
     
    Signature:Braden M Leonard
    Name/Title:Braden M Leonard - Managing Member
    Date:12/16/2024
    Get the next $AVIR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AVIR

    DatePrice TargetRatingAnalyst
    8/13/2024$2.00 → $6.88Underweight → Equal-Weight
    Morgan Stanley
    8/10/2023Neutral → Underweight
    JP Morgan
    3/2/2022$10.00 → $8.00Neutral
    JP Morgan
    3/1/2022$10.00 → $9.00Market Perform
    SVB Leerink
    2/16/2022$11.00 → $10.00Market Perform
    SVB Leerink
    1/6/2022$14.00 → $7.00Equal-Weight → Underweight
    Morgan Stanley
    11/18/2021Outperform → Mkt Perform
    SVB Leerink
    11/18/2021$11.00Outperform → Market Perform
    SVB Leerink
    More analyst ratings

    $AVIR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Berger Franklin M bought $81,498 worth of shares (25,000 units at $3.26), increasing direct ownership by 6% to 476,897 units (SEC Form 4)

    4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    1/17/25 2:30:36 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Berger Franklin M decreased direct ownership by 1% to 476,897 units (SEC Form 4)

    4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    1/17/25 8:03:19 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Atea Pharmaceuticals to Highlight 2026 Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference

    Phase 3 Topline Results for Potential Best-in-Class Regimen for Treatment of HCV on Track for 2026 Topline Results from North American Phase 3 C-BEYOND Trial Expected Mid-2026; Results from C-FORWARD Trial Outside North America Expected Year-End 2026 C-BEYOND and C-FORWARD Are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV Initiation of HEV Phase 1 Clinical Program for Product Candidate AT-587 Anticipated Mid-2026 BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious

    1/8/26 7:00:00 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference

    BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea, together with other members of the Atea management team, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 7:30 a.m. PT in San Francisco, CA. A live webcast of the presentation will be available here and on the Company's website at https://ir.ateapharma.com. An archived webcast will be available on Atea's w

    1/6/26 7:00:00 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

    Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside North America, Enrollment Completion Expected Mid-2026 with Topline Results Anticipated Year-End 2026 C-BEYOND AND C-FORWARD are the First Global Phase 3 Head-to-Head Trials of Direct-Acting Antivirals for Treatment of HCV BOSTON, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced completion o

    12/22/25 7:00:00 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by Atea Pharmaceuticals Inc.

    SCHEDULE 13G - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    2/9/26 2:02:27 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)

    1/8/26 9:05:09 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.

    SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    12/5/25 2:03:43 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Atea Pharmaceuticals upgraded by Morgan Stanley with a new price target

    Morgan Stanley upgraded Atea Pharmaceuticals from Underweight to Equal-Weight and set a new price target of $6.88 from $2.00 previously

    8/13/24 7:25:26 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals downgraded by JP Morgan

    JP Morgan downgraded Atea Pharmaceuticals from Neutral to Underweight

    8/10/23 6:17:18 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    JP Morgan reiterated coverage on Atea Pharmaceuticals with a new price target

    JP Morgan reiterated coverage of Atea Pharmaceuticals with a rating of Neutral and set a new price target of $8.00 from $10.00 previously

    3/2/22 10:09:39 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Horga Maria Arantxa converted options into 51,283 shares and covered exercise/tax liability with 16,073 shares, increasing direct ownership by 58% to 96,086 units (SEC Form 4)

    4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    2/3/26 7:53:00 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Commercial Officer Vavricka John converted options into 42,083 shares and covered exercise/tax liability with 11,570 shares, increasing direct ownership by 59% to 82,594 units (SEC Form 4)

    4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    2/3/26 7:47:27 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Development Officer Hammond Janet Mj converted options into 58,050 shares and covered exercise/tax liability with 14,136 shares, increasing direct ownership by 52% to 127,665 units (SEC Form 4)

    4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)

    2/3/26 7:46:49 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    Leadership Updates

    Live Leadership Updates

    View All

    ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman

    ReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Howard Berman, Ph.D., as Executive Chairman of the ReAlta Life Sciences Board of Directors, effective immediately. "We are delighted to welcome Howard to ReAlta at a pivotal moment for the Company as we move towards meaningful catalysts," said Kenji Cunnion, M.D., MPH, Co-Founder, Chief Medical Officer and Board Member of ReAlta. "His proven track record in advancing innovative immunology-based therapies and creatin

    11/25/25 8:00:00 AM ET
    $AVIR
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

    BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

    4/17/25 7:00:00 AM ET
    $AVIR
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

    BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

    2/24/25 7:00:00 AM ET
    $AVIR
    $LQDA
    $KDMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    $AVIR
    Financials

    Live finance-specific insights

    View All

    Atea Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

    Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North America Trial Expected Mid-2026  New Data Show Bemnifosbuvir Has Unique Dual Mechanism Against HCV New Data Presented at The Liver Meeting®, the Annual Meeting of AASLD, Support Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Therapy for the Treatment of HCV Company Announces New Hepatitis E Virus (HEV) Development Program Company Holding Conference Call Today at 4:30 PM ET Company Hosting HCV KOL Event November 13th at 10 AM ET BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceut

    11/12/25 4:05:00 PM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals to Host Third Quarter 2025 Financial Results and Business Update Conference Call on November 12, 2025

    BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Wednesday, November 12, 2025, at 4:30 p.m. ET to report financial results for the third quarter ended September 30, 2025, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals we

    11/5/25 7:00:00 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update Conference Call on August 7, 2025

    BOSTON, July 31, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, August 7, 2025, at 4:30 p.m. ET to report financial results for the second quarter ended June 30, 2025, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website

    7/31/25 7:00:00 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AVIR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

    SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    11/15/24 10:34:54 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc.

    SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    11/12/24 9:50:14 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Atea Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)

    2/15/24 11:35:08 AM ET
    $AVIR
    Biotechnology: Pharmaceutical Preparations
    Health Care